Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.6896 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3423 | 0.4963 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3423 | 0.3423 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3423 | 0.3423 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.6896 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3423 | 0.3423 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3423 | 0.3423 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3423 | 0.4963 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3423 | 0.4963 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3423 | 0.3423 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3423 | 0.3423 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3423 | 0.4963 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3423 | 0.4963 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3423 | 0.4963 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3423 | 0.3423 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.6896 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | = 4.97 uM | PUBCHEM_BIOASSAY: Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504586] | ChEMBL. | No reference |
Potency (functional) | 0.0517 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.